Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trialFunding secured for follow-on tree (Fagales) pollen program MY010 Schlieren/Zurich, Switzerland, May 19, ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply ...

Late-stage productivity improved in 2025, but total clinical development duration rose to 10 years, indicating non-structural ...

Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and ...

CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens GenoSafe’s role as a transatlantic analytical partner ...

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a ...

Clinical trials are the irreplaceable engine of drug development and a bedrock of modern medicine, yet patient enrollment ...

After more than two years of pandemic-driven growth, Labcorp is shipping off its clinical development arm as a standalone, public company. The spinoff—for now, dubbed the “clinical development ...

The initiative is initially supporting solid tumour oncology projects, focusing on indications such as colon and lung.

Nexentis Technologies Inc. (NASDAQ: NXTS) ('Nexentis' or the 'Company'), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today ...

In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40 ...